Format

Send to

Choose Destination
Future Oncol. 2009 Feb;5(1):43-50. doi: 10.2217/14796694.5.1.43.

Customizing the targeting of IGF-1 receptor.

Author information

1
Thomas Jefferson University, Kimmel Cancer Center, Bluemle Life Sciences Center, Philadelphia, PA 1910, USA. r_baserga@mail.jci.tju.edu

Abstract

The type 1 IGF receptor (IGF-IR) is activated by two ligands, IGF-1 and IGF-2, and by insulin at supraphysiological concentrations. It plays a significant role in the growth of normal and abnormal cells, and antibodies against the IGF-IR are now in clinical trials. Targeting of the IGF-IR in cancer cells (by antibodies or other means) can be improved by the appropriate selection of responsive tumors. This review focuses on the optimization of IGF-IR targeting in human cancer.

PMID:
19243297
DOI:
10.2217/14796694.5.1.43
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center